These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27335098)

  • 1. Brain atrophy measurements should be used to guide therapy monitoring in MS - YES.
    Zivadinov R; Dwyer MG; Bergsland N
    Mult Scler; 2016 Oct; 22(12):1522-1524. PubMed ID: 27335098
    [No Abstract]   [Full Text] [Related]  

  • 2. Brain atrophy measurements should be used to guide therapy monitoring in MS - NO.
    Barkhof F
    Mult Scler; 2016 Oct; 22(12):1524-1526. PubMed ID: 27335096
    [No Abstract]   [Full Text] [Related]  

  • 3. The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately--yes.
    Geurts JJ
    Mult Scler; 2012 May; 18(5):559-60. PubMed ID: 22547412
    [No Abstract]   [Full Text] [Related]  

  • 4. Brain atrophy in multiple sclerosis: therapeutic, cognitive and clinical impact.
    Rojas JI; Patrucco L; Miguez J; Cristiano E
    Arq Neuropsiquiatr; 2016 Mar; 74(3):235-43. PubMed ID: 27050854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): Yes.
    Rudick RA; Fisher E
    Mult Scler; 2013 Jul; 19(8):1003-4. PubMed ID: 23818018
    [No Abstract]   [Full Text] [Related]  

  • 6. Rate of brain atrophy in benign vs early multiple sclerosis.
    Gauthier SA; Berger AM; Liptak Z; Duan Y; Egorova S; Buckle GJ; Glanz BI; Khoury SJ; Bakshi R; Weiner HL; Guttmann CR
    Arch Neurol; 2009 Feb; 66(2):234-7. PubMed ID: 19204160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain atrophy: an in-vivo measure of disease activity in multiple sclerosis.
    Radü EW; Bendfeldt K; Mueller-Lenke N; Magon S; Sprenger T
    Swiss Med Wkly; 2013; 143():w13887. PubMed ID: 24264439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately--no.
    Filippi M; Rocca MA
    Mult Scler; 2012 May; 18(5):557-8. PubMed ID: 22547411
    [No Abstract]   [Full Text] [Related]  

  • 9. Brain atrophy assessment in multiple sclerosis: importance and limitations.
    Giorgio A; Battaglini M; Smith SM; De Stefano N
    Neuroimaging Clin N Am; 2008 Nov; 18(4):675-86, xi. PubMed ID: 19068408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gray matter atrophy in multiple sclerosis: a longitudinal study.
    Fisher E; Lee JC; Nakamura K; Rudick RA
    Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis.
    Tauhid S; Neema M; Healy BC; Weiner HL; Bakshi R
    J Neurol Sci; 2014 Nov; 346(1-2):250-4. PubMed ID: 25220114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cognitive impairment in multiple sclerosis].
    Karlińska I; Selmaj K
    Neurol Neurochir Pol; 2005; 39(2):125-33. PubMed ID: 15871058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal associations between brain structural changes and fatigue in early MS.
    Nourbakhsh B; Azevedo C; Nunan-Saah J; Maghzi AH; Spain R; Pelletier D; Waubant E
    Mult Scler Relat Disord; 2016 Jan; 5():29-33. PubMed ID: 26856940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Grey matter pathology in clinically early multiple sclerosis: evidence from magnetic resonance imaging.
    Chard D; Miller D
    J Neurol Sci; 2009 Jul; 282(1-2):5-11. PubMed ID: 19201002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring brain atrophy in multiple sclerosis.
    De Stefano N; Battaglini M; Smith SM
    J Neuroimaging; 2007 Apr; 17 Suppl 1():10S-15S. PubMed ID: 17425728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.
    Tauhid S; Chu R; Sasane R; Glanz BI; Neema M; Miller JR; Kim G; Signorovitch JE; Healy BC; Chitnis T; Weiner HL; Bakshi R
    J Neurol; 2015 Nov; 262(11):2425-32. PubMed ID: 26205635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of brain volume in MS. MRI and pathology findings.
    Lycklama à Nijeholt GJ
    J Neurol Sci; 2005 Jun; 233(1-2):199-202. PubMed ID: 15949505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis.
    Lazeron RH; Boringa JB; Schouten M; Uitdehaag BM; Bergers E; Lindeboom J; Eikelenboom MI; Scheltens PH; Barkhof F; Polman CH
    Mult Scler; 2005 Oct; 11(5):524-31. PubMed ID: 16193889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis.
    Bakshi R; Dandamudi VS; Neema M; De C; Bermel RA
    J Neuroimaging; 2005; 15(4 Suppl):30S-45S. PubMed ID: 16385017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of linear cerebral atrophy markers in multiple sclerosis.
    Butzkueven H; Kolbe SC; Jolley DJ; Brown JY; Cook MJ; van der Mei IA; Groom PS; Carey J; Eckholdt J; Rubio JP; Taylor BV; Mitchell PJ; Egan GF; Kilpatrick TJ
    J Clin Neurosci; 2008 Feb; 15(2):130-7. PubMed ID: 18068987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.